1. Pidilite Industries:
Geojit BNP Paribas reiterates its ‘Buy’ rating on this adhesives company with a target price of Rs 3,447, an upside of 11.2%. Analyst Anil R highlights that the tile adhesive market is growing at nearly twice the pace of India’s GDP. Pidilite is also expanding approximately 1.5 times faster than the market, with rural demand consistently outpacing urban growth in recent quarters.
Pidilite Industries’ Q1FY26 revenue rose 10.5% YoY to Rs 3,753 crore, supported by higher sales across its consumer and business-to-business (B2B) segments. The consumer and bazaar segment, which contributes the majority of revenue, grew 10% YoY, while B2B revenue increased 11%. Management noted that the domestic business benefited from favourable monsoon conditions, steady demand, and lower input costs, while international subsidiaries recorded 6.5% growth.
The analyst expects Pidilite to continue delivering strong volume-led growth, supported by ongoing investments in its brands and supply chain. However, the company remains cautious about potential headwinds from geopolitical developments and uncertainty around global tariffs.
2. Dabur India:
Sharekhan retains its ‘Buy’ rating on this FMCG company with a target price of Rs 623, an upside of 19.3%. Analysts note that the company’s Q1FY26 performance was muted, as unseasonal rains during the peak summer months impacted its beverages and glucose sales. Revenue grew only 1.7% YoY to Rs 3,405 crore; but excluding its seasonal products, revenue rose 7%.
The home and personal care segment grew 5%, led by oral care, home care, and skincare. Healthcare revenue declined 4.4% but rose 2.7% when excluding glucose, thanks to growth in its power brands such as honey, chyawanprash, and Honitus (cough syrup) . Dabur reported market share gains across 95% of its portfolio.
The management stated that rural growth outpaced urban for the fifth straight quarter, with a 390 bps lead in Q1. For Q2, the company expects double-digit revenue growth, supported by premiumisation, new launches, and a focus on its power brands. As part of its Vision FY28 strategy, Dabur has exited several margin-dilutive categories, including tea, adult diapers, sanitiser, and breakfast cereals. These businesses collectively contributed only Rs 8 crore in sales in FY25.
3. NTPC:
ICICI Securities reiterates its ‘Buy’ rating on this power company with a target price of Rs 439, an upside of 31.8%. NTPC is transforming from a thermal power giant into a diversified power player. It has raised its target capacity to 149 gigawatt (GW) by FY32 (from 130 GW) with a planned capex of Rs 7 lakh crore.
While the company plans 26-27 GW of coal-based capacity expansion, it is targeting 60 GW of renewable capacity, led by its listed green subsidiary, NTPC Green Energy. The company is also investing in green hydrogen, energy storage, and nuclear energy, with a long-term nuclear energy target of 30 GW by FY47.
Analysts Mohit Kumar and Mahesh Patil expect the company to benefit from India’s 6% annual power demand growth. They note that thermal capacity will remain critical in the medium term to meet peak demand, which supports NTPC’s expansion plans. They also highlight that execution has improved in FY26, with 3 GW already commissioned so far, compared to 4 GW commissioned during the entire FY25.
4. Godrej Consumer Products:
Emkay maintains a ‘Buy’ rating on this FMCG major, with a target price of Rs 1,400, an upside of 11.3%. Analyst Nitin Gupta notes that GCPL is focused on volume-led growth in India and international markets while improving margins. At Emkay Confluence 2025, Vishal Kedia, Head of Global Strategy, shared that the company is investing early in a few categories ahead of the demand curve to capture growth opportunities.
In India, Gupta sees high-growth potential in household insecticides (HI), soaps, and personal wash. HI, contributing one-third of India’s revenue, could deliver high single-digit to low double-digit growth. Soaps, also a third of revenue, are under margin pressure due to palm oil inflation, with price hikes expected from Q3FY26. New initiatives like body wash, air fresheners, and deodorants are being tested and priced to boost adoption.
Internationally, the company faces margin pressure in Indonesia due to competition, with margins expected to recover to 22-24% in the medium term. Africa is expected to achieve low double-digit growth and margins of 17-18% over the next 4-5 years.
5. Sharda Cropchem:
Khambatta Securities upgrades its rating to ‘Buy’ on this agrochemicals producer with a higher target price of Rs 1,162, an upside of 20.1%. In Q1FY26, the company's revenue increased 26.5% YoY to Rs 984.8 crore, beating Forecaster estimates by 11%. The non-agricultural and agrochemical segments grew, boosting revenue growth. The company’s EBITDA margin expanded 356 bps to 14.4%.
Management's outlook for FY26 is to grow the topline by approximately 15% and maintain healthy EBITDA margins in the range of 15%-18%. They plan a capex of Rs 400-450 crore for the year to support new product registrations. The global agrochemical market is showing signs of recovery, with inventories returning to normal levels.
Analysts at Khambatta Securities expect revenue, EBITDA, and net profit to grow at a CAGR of 15.9%, 17.3%, and 38.4%, respectively, driven by the company’s plans to add new product registrations.
Note: These recommendations are from various analysts and are not recommendations by Trendlyne.
(You can find all analyst picks here)
